

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/009163 A1

(43) International Publication Date
13 January 2022 (13.01.2022)

(51) International Patent Classification:

A61K 31/497 (2006.01) A61P 13/12 (2006.01)
A61K 31/70 (2006.01)

(21) International Application Number:

PCT/IB2021/056177

(22) International Filing Date:

09 July 2021 (09.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/050,147 10 July 2020 (10.07.2020) US
63/196,793 04 June 2021 (04.06.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85
Södertälje (SE).

(72) Inventors: **GREASLEY, Peter**; Astrazeneca AB,
SE-151-85 Södertälje (SE). **AHLSTRÖM, Christine**;
Astrazeneca AB, SE-151-85 Södertälje (SE). **SKRTIC,**
Stanko; Astrazeneca AB, SE-151-85 Södertälje (SE).
MENZIES, Robert; Astrazeneca AB, SE-151-85 Södertäl-
je (SE).

(74) Agent: **LEESE, Mathew**; Astrazeneca Intellectual Prop-
erty, Milstein Building, Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

WO 2022/009163 A1

(54) Title: COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

(57) Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.